Can you get high on Zanaprin?
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
Can you get high on Zanaprin?
No, you can not get high on Zanaprin. It is a supplement for the management of anxiety and is not an actual medication. It consists of natural ingredients to control the excessive neuronal activity in your brain and relax your mind (1).
Zanaprin can calm some people down just like Benzodiazepines do, but it is not as strong as those meds are. Supplements are not generally strong and they take longer to deal with your symptoms (2). This is why Zanaprin is not known to induce euphoria.
However, people may start to misuse this supplement because of the calming sensation it gives them – which may cause side effects. Make sure you don’t take Zanaprin with anti-anxiety medications, which may double the calming effect.
If you have clinical anxiety or any other psychological illness, don’t take Zanaprin without your doctor’s approval.
How is Zanaprin different from drugs that get you high?
Zanaprin is different from drugs that get you high because it doesn’t contain any substances that produce a euphoric or altered state of mind. It is a natural supplement that is often used to help with anxiety and stress.
Drugs that are known to get you high, like recreational drugs or substances such as marijuana, cocaine, or ecstasy, often contain chemicals that affect the brain’s functioning in a way that can induce feelings of pleasure, altered perception, or intense excitement (3,4).
The mechanism of action for drugs that get you high involves interacting with specific receptors in the brain, such as cannabinoid receptors for marijuana or dopamine receptors for cocaine (3,4).
By binding to these receptors, these drugs can cause an increased release or inhibition of certain neurotransmitters, leading to the desired effects (3,4).
Zanaprin, on the other hand, works in a different way. Its ingredients, such as amino acids, herbal extracts, and vitamins, are carefully chosen to support a sense of calmness and relaxation without inducing any significant changes in brain chemistry (2).
In simpler terms, Zanaprin helps create a feeling of relaxation and calmness without altering your brain chemistry in a way that would cause a “high” or euphoric sensation.
It focuses more on providing a natural sense of well-being rather than inducing an altered state of consciousness.
Can Zanaprin cause side effects?
Zanaprin, although it is generally well-tolerated, may cause mild side effects, including (1):
- Drowsiness or sedation: Some people may experience feelings of drowsiness or excessive tiredness after taking Zanaprin. It’s advisable to be cautious when performing activities that require alertness, such as driving or operating machinery until you understand how the supplement affects you.
- Dry mouth: A few individuals may experience a dry or parched sensation in the mouth after taking Zanaprin. Staying hydrated and drinking enough fluids can help alleviate this discomfort.
- Digestive disturbances: In rare cases, Zanaprin may cause digestive issues such as stomach discomfort, nausea, or changes in bowel movements. If these symptoms persist or become bothersome, it’s recommended to consult with a healthcare professional.
It’s important to remember that these potential side effects are not experienced by everyone using Zanaprin, and they are generally mild and temporary.
If you have any concerns or notice any unusual experiences while taking Zanaprin, it’s always best to consult with a healthcare professional.
Was this helpful?
References
1.-
Zanaprin (Manufacturer’s website)
2.-
Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J. 2010 Oct 7;9:42. doi: 10.1186/1475-2891-9-42. PMID: 20929532; PMCID: PMC2959081. https://pubmed.ncbi.nlm.nih.gov/20929532/
3.-
Aro HJ, Hussain A, Bobrin BD. Controlled Substances. 2023 Apr 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32119270. https://www.ncbi.nlm.nih.gov/books/NBK554383
4.-
Albertson TE. Recreational drugs of abuse. Clin Rev Allergy Immunol. 2014 Feb;46(1):1-2. doi: 10.1007/s12016-013-8382-y. PMID: 23832389. https://pubmed.ncbi.nlm.nih.gov/23832389/
